Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 103

1.

Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.

Gu Y, Moroy G, Paul JL, Rebillat AS, Dierssen M, de la Torre R, Cieuta-Walti C, Dairou J, Janel N.

Int J Mol Sci. 2020 Feb 19;21(4). pii: E1404. doi: 10.3390/ijms21041404.

2.

Preface.

Mara D, Yann H.

Prog Brain Res. 2020;251:xv. doi: 10.1016/S0079-6123(20)30015-7. No abstract available.

PMID:
32057314
3.

Plasticity as a therapeutic target for improving cognition and behavior in Down syndrome.

Martínez Cué C, Dierssen M.

Prog Brain Res. 2020;251:269-302. doi: 10.1016/bs.pbr.2019.11.001. Epub 2019 Dec 6.

PMID:
32057310
4.

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome.

Rueda N, Flórez J, Dierssen M, Martínez-Cué C.

Prog Brain Res. 2020;251:245-268. doi: 10.1016/bs.pbr.2019.10.001. Epub 2019 Nov 1.

PMID:
32057309
5.

A specific prelimbic-nucleus accumbens pathway controls resilience versus vulnerability to food addiction.

Domingo-Rodriguez L, Ruiz de Azua I, Dominguez E, Senabre E, Serra I, Kummer S, Navandar M, Baddenhausen S, Hofmann C, Andero R, Gerber S, Navarrete M, Dierssen M, Lutz B, Martín-García E, Maldonado R.

Nat Commun. 2020 Feb 7;11(1):782. doi: 10.1038/s41467-020-14458-y.

6.

DYRK1A Overexpression Alters Cognition and Neural-Related Proteomic Pathways in the Hippocampus That Are Rescued by Green Tea Extract and/or Environmental Enrichment.

De Toma I, Ortega M, Aloy P, Sabidó E, Dierssen M.

Front Mol Neurosci. 2019 Nov 15;12:272. doi: 10.3389/fnmol.2019.00272. eCollection 2019.

7.

Effect of epigallocatechin gallate on the body composition and lipid profile of down syndrome individuals: Implications for clinical management.

Xicota L, Rodríguez J, Langohr K, Fitó M, Dierssen M, de la Torre R; TESDAD study group.

Clin Nutr. 2019 Jun 8. pii: S0261-5614(19)30255-9. doi: 10.1016/j.clnu.2019.05.028. [Epub ahead of print]

PMID:
31229326
8.

Pergola-web: a web server for the visualization and analysis of longitudinal behavioral data using repurposed genomics tools and standards.

Espinosa-Carrasco J, Pulido TH, Erb I, Dierssen M, Ponomarenko J, Notredame C.

Nucleic Acids Res. 2019 Jul 2;47(W1):W600-W604. doi: 10.1093/nar/gkz414.

9.

A phase 1, randomized double-blind, placebo controlled trial to evaluate safety and efficacy of epigallocatechin-3-gallate and cognitive training in adults with Fragile X syndrome.

de la Torre R, de Sola S, Farré M, Xicota L, Cuenca-Royo A, Rodriguez J, León A, Langohr K, Gomis-González M, Hernandez G, Esteba S, Del Hoyo L, Sánchez-Gutiérrez J, Cortés MJ, Ozaita A, Espadaler JM, Novell R, Martínez-Leal R, Milá M, Dierssen M; TESXF Study Group.

Clin Nutr. 2020 Feb;39(2):378-387. doi: 10.1016/j.clnu.2019.02.028. Epub 2019 Mar 25.

PMID:
30962103
10.

Paving the Way for Therapy: The Second International Conference of the Trisomy 21 Research Society.

Reeves RH, Delabar J, Potier MC, Bhattacharyya A, Head E, Lemere C, Dekker AD, De Deyn P, Caviedes P, Dierssen M, Busciglio J.

Mol Syndromol. 2019 Jan;9(6):279-286. doi: 10.1159/000494231. Epub 2018 Oct 30.

11.

Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome.

Navarro-Romero A, Vázquez-Oliver A, Gomis-González M, Garzón-Montesinos C, Falcón-Moya R, Pastor A, Martín-García E, Pizarro N, Busquets-Garcia A, Revest JM, Piazza PV, Bosch F, Dierssen M, de la Torre R, Rodríguez-Moreno A, Maldonado R, Ozaita A.

Neurobiol Dis. 2019 May;125:92-106. doi: 10.1016/j.nbd.2019.01.014. Epub 2019 Jan 25.

PMID:
30685352
12.

Metabolomics predicts the pharmacological profile of new psychoactive substances.

Olesti E, De Toma I, Ramaekers JG, Brunt TM, Carbó ML, Fernández-Avilés C, Robledo P, Farré M, Dierssen M, Pozo ÓJ, de la Torre R.

J Psychopharmacol. 2019 Mar;33(3):347-354. doi: 10.1177/0269881118812103. Epub 2018 Nov 19.

PMID:
30451567
13.

Pergola: Boosting Visualization and Analysis of Longitudinal Data by Unlocking Genomic Analysis Tools.

Espinosa-Carrasco J, Erb I, Hermoso Pulido T, Ponomarenko J, Dierssen M, Notredame C.

iScience. 2018 Nov 30;9:244-257. doi: 10.1016/j.isci.2018.10.023. Epub 2018 Oct 26.

14.

Translating molecular advances in Down syndrome and Fragile X syndrome into therapies.

Faundez V, De Toma I, Bardoni B, Bartesaghi R, Nizetic D, de la Torre R, Cohen Kadosh R, Herault Y, Dierssen M, Potier MC; Down Syndrome and Other Genetic Developmental Disorders ECNP Network.

Eur Neuropsychopharmacol. 2018 Jun;28(6):675-690. doi: 10.1016/j.euroneuro.2018.03.006. Epub 2018 Jun 7. Review.

PMID:
29887288
15.

Mutations in L-type amino acid transporter-2 support SLC7A8 as a novel gene involved in age-related hearing loss.

Espino Guarch M, Font-Llitjós M, Murillo-Cuesta S, Errasti-Murugarren E, Celaya AM, Girotto G, Vuckovic D, Mezzavilla M, Vilches C, Bodoy S, Sahún I, González L, Prat E, Zorzano A, Dierssen M, Varela-Nieto I, Gasparini P, Palacín M, Nunes V.

Elife. 2018 Jan 22;7. pii: e31511. doi: 10.7554/eLife.31511.

16.

Time-course and dynamics of obesity-related behavioral changes induced by energy-dense foods in mice.

Espinosa-Carrasco J, Burokas A, Fructuoso M, Erb I, Martín-García E, Gutiérrez-Martos M, Notredame C, Maldonado R, Dierssen M.

Addict Biol. 2018 Mar;23(2):531-543. doi: 10.1111/adb.12595. Epub 2018 Jan 10.

PMID:
29318700
17.

Extinction and reinstatement of an operant responding maintained by food in different models of obesity.

Burokas A, Martín-García E, Espinosa-Carrasco J, Erb I, McDonald J, Notredame C, Dierssen M, Maldonado R.

Addict Biol. 2018 Mar;23(2):544-555. doi: 10.1111/adb.12597. Epub 2017 Dec 28.

PMID:
29282813
18.

Loss of SIRT2 leads to axonal degeneration and locomotor disability associated with redox and energy imbalance.

Fourcade S, Morató L, Parameswaran J, Ruiz M, Ruiz-Cortés T, Jové M, Naudí A, Martínez-Redondo P, Dierssen M, Ferrer I, Villarroya F, Pamplona R, Vaquero A, Portero-Otín M, Pujol A.

Aging Cell. 2017 Dec;16(6):1404-1413. doi: 10.1111/acel.12682. Epub 2017 Oct 5.

19.

Anomalous White Matter Structure and the Effect of Age in Down Syndrome Patients.

Fenoll R, Pujol J, Esteba-Castillo S, de Sola S, Ribas-Vidal N, García-Alba J, Sánchez-Benavides G, Martínez-Vilavella G, Deus J, Dierssen M, Novell-Alsina R, de la Torre R.

J Alzheimers Dis. 2017;57(1):61-70. doi: 10.3233/JAD-161112.

PMID:
28222523
20.

New murine Niemann-Pick type C models bearing a pseudoexon-generating mutation recapitulate the main neurobehavioural and molecular features of the disease.

Gómez-Grau M, Albaigès J, Casas J, Auladell C, Dierssen M, Vilageliu L, Grinberg D.

Sci Rep. 2017 Feb 7;7:41931. doi: 10.1038/srep41931.

Supplemental Content

Loading ...
Support Center